Evidence map›Paper›PMID 36344430›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022

Self-Cooperative Prodrug Nanovesicles Migrate Immune Evasion to Potentiate Chemoradiotherapy in Head and Neck Cancer.

Yun Zhu, Shunan Zhang, Yi Lai, Jiaxing Pan, Fangmin Chen, Tingting Wang, Fengyang Wang, Zhiai Xu, Wenjun Yang, Haijun Yu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Yun ZhuDepartment of Oral and Maxillofacial-Head and Neck Oncology, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine; National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai, 200011, China.
Shunan ZhangCenter of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Yi LaiCenter of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Jiaxing PanCenter of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Fangmin ChenCenter of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Tingting WangDepartment of Medical Ultrasound, Shanghai Tenth People's Hospital; Tongji University, Shanghai, 200072, China.
Fengyang WangDepartment of Medical Ultrasound, Shanghai Tenth People's Hospital; Tongji University, Shanghai, 200072, China.
Zhiai XuSchool of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200241, China.
Wenjun YangDepartment of Oral and Maxillofacial-Head and Neck Oncology, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine; National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai, 200011, China.
Haijun YuCenter of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.ORCID 0000-0002-3398-0880
Chinese Academy of Sciences · CNShanghai Jiao Tong University · CNTongji University · CNEast China Normal University · CNShanghai Medical College of Fudan University · CN

Funding

Changchun Institute of Applied ChemistryChina Postdoctoral Science Foundation 2021M700157Chinese Academy of Sciences 2019-027Lingang Laboratory LG-QS-202206-04National Natural Science Foundation of China 51873228National Natural Science Foundation of China 52003194National Natural Science Foundation of China 82102915Open Research Fund of State Key Laboratory of Polymer Physics and ChemistryScience Foundation of Shanghai Science and Technology Commission 20430711800Science Foundation of Shanghai Science and Technology Commission 21ZR1437900Shanghai Ninth people's hospitalShanghai Post-Doctoral Excellence Program 2021424
6 · The paper itself

Abstract

Chemoradiotherapy is the standard of care for the clinical treatment of locally advanced head and neck cancers. However, the combination of ion radiation with free chemotherapeutics yields unsatisfactory therapeutic output and severe side effects due to the nonspecific biodistribution of the anticancer drugs. Herein, a self-cooperative prodrug nanovesicle is reported for highly tumor-specific chemoradiotherapy. The nanovesicles integrating a prodrug of oxaliplatin (OXA) can passively accumulate at the tumor site and penetrate deep into the tumor mass via matrix metalloproteinase 2-mediated cleavage of the polyethylene glycol corona. The OXA prodrug can be restored inside the tumor cells with endogenous glutathione to trigger immunogenic cell death (ICD) of the tumor cells and sensitize the tumor to ion radiation. The nanovesicles can be further loaded with the JAK inhibitor ruxolitinib to abolish chemoradiotherapy-induced programmed death ligand 1 (PD-L1) upregulation on the surface of the tumor cells, thereby prompting chemoradiotherapy-induced immunotherapy by blocking the interferon gamma-Janus kinase-signal transducer and activator of transcription axis. The prodrug nanoplatform reported herein might present a novel strategy to cooperatively enhance chemoradiotherapy of head and cancer and overcome PD-L1-dependent immune evasion.

Indexed as

Head and Neck NeoplasmsProdrugsB7-H1 AntigenChemoradiotherapyHumansImmune EvasionMatrix Metalloproteinase 2OxaliplatinTissue DistributionB7-H1 AntigenMatrix Metalloproteinase 2OxaliplatinProdrugschemoradiotherapycooperative therapyhead and neck cancerimmune evasionimmunogenic cell death

Identifiers

PMID36344430
PMCPMC9798966
OpenAlexW4308394083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.